Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + statin
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Pioglitazone + statin** is a combination drug regimen comprising pioglitazone, a thiazolidinedione that acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, and a statin, which is an inhibitor of hydroxymethylglutaryl-CoA reductase. Pioglitazone improves insulin sensitivity, modulates inflammation, and enhances adiponectin in patients with insulin resistance or metabolic syndrome. Statins, such as simvastatin or atorvastatin, lower LDL cholesterol, raise HDL cholesterol, and decrease cardiovascular events by reducing cholesterol synthesis in the liver. Several clinical studies demonstrate that combining pioglitazone with a statin exerts additive anti-inflammatory effects, as measured by biomarkers like C-reactive protein and matrix metalloproteinase-9, with complementary benefits on lipid and metabolic profiles in patients with cardiovascular risk factors, with or without diabetes[1][2][4].
- Brand names
- pioglitazone + statin
- Other names
- pioglitazone + statin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on pioglitazone + statin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + statin.